Consolidated Cash Flow Statement

Profit after tax

883.0

927.6

Depreciation/amortization/impairment losses/reversals of impairments

980.5

996.8

Changes in inventories

17.8

–117.1

Changes in trade accounts receivable

–78.3

–31.9

Changes in trade accounts payable

–98.5

77.3

Changes in provisions

0.2

35.3

Changes in other assets and liabilities

–132.6

–55.5

Neutralization of gain/loss on disposals of assets

–12.2

–50.0

Other non-cash income and expenses

4.4

2.6

Net cash flows from operating activities

1,564.2

1,785.1

Payments for investments in intangible assets

–74.1

–66.3

Payments from the disposal of intangible assets¹

0.6

0.8

Payments for investments in property, plant and equipment

–269.9

–235.3

Payments from the sale of property, plant and equipment¹

6.3

266.2

Payments for investments in financial assets¹

–1,852.2

–899.7

Payments for the obtainment of control over AZ Electronic Materials S.A. less acquired cash and cash equivalents

–1,419.4

–

Payments for other acquisitions

–

–15.1

Payments from the disposal of other financial assets¹

3,090.2

337.8

Payments from the divestment of the Discovery and Development Solutions business field

20.9

–

Net cash flows from investing activities

–497.5

–611.7

Dividend payments to Merck KGaA shareholders¹

–122.8

–109.9

Dividend payments to non-controlling interests¹

–3.0

–3.3

Withdrawals from retained earnings by E. Merck KG¹

–382.7

–304.5

Payments from new borrowings of financial liabilities from E. Merck¹

213.6

196.9

Payments for the acquisition of shares in AZ Electronic Materials S.A. after obtainment of control

–351.4

–

Repayment of bonds

–

–750.0

Changes in other current and non-current financial liabilities

–111.7

4.3

Net cash flows from financing activities

–758.1

–966.4

Changes in cash and cash equivalents

308.7

207.0

Changes in cash and cash equivalents due to currency translation

48.8

–21.4

Cash and cash equivalents as of January 1

980.8

729.7

Cash and cash equivalents as of September 30

1,338.3

915.3

Plus cash and cash equivalents included in assets held for sale

–

–

Cash and cash equivalents as of September 30
(consolidated balance sheet)

1,338.3

915.3